BERKELEY HEIGHTS, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Genta Incorporated , announced that Genasense(R) (oblimersen sodium) Injection, the Company’s lead anticancer compound, will be featured in presentations at the twenty-third annual symposium of the Chemotherapy Foundation in New York, NY. Investigators will review and discuss the activity and safety of Genasense in combination with chemotherapy from the Company’s pivotal clinical studies in malignant melanoma and chronic lymphocytic leukemia. Highlighted presentations include the following:
-- Tuesday, November 2, 2005; 9:35 AM Bcl-2 Antisense Therapy in Chronic Lymphocytic Leukemia. Kanti R. Rai, M.D., Chief, Hematology and Oncology, North Shore/Long Island Jewish Medical Center, and Professor of Medicine, Albert Einstein College of Medicine. -- Friday, November 4, 2005; 2:35 P.M. Bcl-2 Antisense Therapy in MelanomaFrank G. Haluska, M.D., Ph.D, Director, Dana-Farber/Partners CancerCare Melanoma Program, and Assistant Professor of Medicine, Harvard Medical School. About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense to evaluate its potential to treat various forms of cancer. In addition, Genta has established a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), which has initiated additional clinical trials. Information about the NCI-sponsored studies can be obtained at: http://www.clinicaltrials.gov/ct/search;jsessionid=50D3886BAAE768BEA0DE36526F6 8083B?term=oblimersen
About Genta
Genta Incorporated is a pharmaceutical company with a diversified product portfolio that is focused on delivering innovative treatments for patients with cancer. The Company’s research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection, the Company’s lead compound from its oligonucleotide program, is currently undergoing late-stage, Phase 3 clinical testing. In 2005, the Company initiated a “rolling” New Drug Application to the Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. The Company has also indicated its intention to submit in 2005 a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for the use of Genasense plus dacarbazine in patients with advanced melanoma. The leading drug in Genta’s small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com.
This press release contains forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company’s Annual Report/Form 10-K for 2004.
Genta Incorporated
CONTACT: Investor Relations, TS Communications Group, LLC,+1-908-286-3980, or info@genta.com; or Media Relations, Greg Tiberend,Richard Lewis Communications, +1-212-827-0020
Web site: http://www.genta.com/
